What is Plaque Psoriasis Treatment Market?
With the growing number of pipeline psoriasis molecules and biologics being released, the demand for plaque psoriasis treatment is expected to soar. Plaque psoriasis is an autoimmune inflammatory disorder that causes excessive skin cell production. Inflamed, elevated, scaly red plaques and lesions characterize the skin. Environmental factors such as sun exposure, smoking, HIV infection, and alcoholism may influence the severity and frequency of psoriasis. In younger psoriasis patients, psoriasis raises the risk of myocardial infarction by three times.
The market study is being classified by Type (Topical Therapy, Phototherapy, Systemic Agents and Biologic Therapies), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.
Allergan (United States), Johnson and Johnson (United States), Amgen (United States), Abbvie (United States), Eli Lilly (United States), Dermira (United States), Novartis (Switzerland), Galectin Therapeutics (United States), Cellceutix (United States), Biogen (United States) and Bayer (Germany) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Plaque Psoriasis Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Plaque Psoriasis Treatment market by Type, Application and Region.
On the basis of geography, the market of Plaque Psoriasis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Pipeline Psoriasis Molecule and the Number of Biologics being Launched
- Increasing Approval of Pipeline Drugs and Supplemental Biologics
- High Cost of Drug Development
- Increased Research and Development Funding
- Growth in the Healthcare Industry Worldwide
In Oct 2020, LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment
In Aug 2020, Novartis announced the European Commission (EC) has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The recommended dose for children up to 50 kg is 75 mg (without a lower weight restriction), and 150 mg for children 50 kg and over (150 mg as a starting dose, which may be increased to 300 mg, if needed).
Key Target Audience
Plaque Psoriasis Treatment Providers, Potential Investors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase